Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project
Author:
Lange BeritORCID, Jaeger Veronika KORCID, Harries ManuelaORCID, Rücker Viktoria, Streeck Hendrik, Blaschke Sabine, Petersmann AstridORCID, Toepfner NicoleORCID, Nauck MatthiasORCID, Hassenstein Max JORCID, Dreier Maren, Von Holt Isabell, Budde AxelORCID, Bartz AntoniaORCID, Ortmann JuliaORCID, Kurosinski Marc-André, Berner ReinhardORCID, Borsche MaxORCID, Brandhorst Gunnar, Brinkmann MelanieORCID, Budde Kathrin, Deckena Marek, Engels Geraldine, Fenzlaff Marc, Härtel Christoph, Hovardovska OlgaORCID, Katalinic AlexanderORCID, Kehl Katja, Kohls MirjamORCID, Krüger Stefan, Lieb Wolfgang, Meyer-Schlinkmann Kristin MORCID, Pischon TobiasORCID, Rosenkranz Daniel, Rübsamen Nicole, Rupp Jan, Schäfer Christian, Schattschneider Mario, Schlegtendal AnneORCID, Schlinkert Simon, Schmidbauer Lena, Schulze-Wundling Kai, Störk Stefan, Tiemann Carsten, Völzke Henry, Winter Theresa, Klein Christine, Liese Johannes, Brinkmann FolkeORCID, Ottensmeyer Patrick FORCID, Reese Jens-PeterORCID, Heuschmann PeterORCID, Karch AndréORCID
Abstract
AbstractDespite the need to generate valid and reliable estimates of protection against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real-time.In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n=33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses (“confirmed exposures”). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest.Most participants were seropositive against the spike antigen; 37% of the participants ≥79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4%-28% of participants having less than three confirmed exposures.Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.
Publisher
Cold Spring Harbor Laboratory
Reference27 articles.
1. Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany—A Blind Spot in Epidemiology?;Infectious Disease Reports,2021 2. High Seroprevalence of SARS-CoV-2 in Preschool Children in July 2022;Dtsch Arztebl Int,2022 3. SARS-CoV-2 Seroprevalence in Germany: A Population-Based Sequential Study in Seven Regions;Deutsches ärzteblatt international,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|